Eosinophilic pulmonary vasculitis as a manifestation of the hyperinflammatory phase of COVID-19

Luecke, Eva; Jeron, Andreas; Kroeger, Andrea; Bruder, Dunja; Stegemann-Koniszewski, Sabine; Jechorek, Doerthe; Borucki, Katrin; Reinhold, Dirk; Reinhold, Annegret; Foellner, Sebastian; Walles, Thorsten; Hachenberg, Thomas; Schreiber, Jens

doi:10.1016/j.jaci.2020.09.026

Cited by 10 publications

(11 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 10 , 11 , 12 Presentation may be extremely variable and, in cases of lung involvement, the differential diagnosis between idiopathic vasculitis and COVID‐19 may be challenging. 8 , 9 On the other hand, there have not yet been any reports of cases of patients whose rheumatic condition has worsened or even relapsed after vaccination against COVID‐19.…”

Section: Discussionmentioning

confidence: 99%

Relapse of microscopic polyangiitis after vaccination against COVID‐19: A case report

Conticini

d’Alessandro

Bergantini

et al. 2021

Journal of Medical Virology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Relapse of microscopic polyangiitis after vaccination against COVID‐19: A case report

Conticini

d’Alessandro

Bergantini

et al. 2021

Journal of Medical Virology

View full text Add to dashboard Cite

“…In a recent post-mortem series of COVID-19 patients, eosinophils were found in the alveolar septs, 62 and several case reports of COVID-19 patients undergoing bronchoalveolar lavage and/or lung biopsy showed significant eosinophilic infiltrates in lungs. 63,64 Taken together, all these observations may provide an additional hypothesis explaining why the use of both omalizumab and anti-Th2 cytokines therapies could further improve the clinical course of COVID-19.…”

Section: Impact Of Anti-th2 Therapy On Covid-19: Potential Mechanismsmentioning

confidence: 90%

Impact of Anti-Type 2 Inflammation Biologic Therapy on COVID-19 Clinical Course and Outcome

Poddighe¹,

Kovzel²

2021

JIR

View full text Add to dashboard Cite

SARS-CoV-2 pandemic had a general and deep impact on the clinical management of chronic diseases, including respiratory and allergic disorders. At the beginning of the pandemic, one of the main concerns was the potential impact of immunosuppressive/immunomodulatory drugs on COVID-19 clinical course. In this review, we aim to summarize and analyze the available clinical evidence from patients treated with anti-type 2 inflammation biologics (including anti-IgE, anti-IL-5 and anti-IL-4 agents), who developed COVID-19. Overall, the treatment with anti-Th2 biologics can be considered safe during COVID-19. It does not worsen the clinical course and outcome of COVID-19, and it may be actually protective somehow from developing severe forms. Moreover, patients treated with these biological agents do not seem to be more prone to get infected by SARS-CoV-2.

show abstract

“…Several isolated incidents of eosinophil-associated complications of COVID-19 have been reported in the literature. Among these cases, Luecke et al [ 105 ] documented a case of isolated pulmonary eosinophilic vasculitis in an older male patient undergoing mechanical ventilation for severe COVID-19. Similarly, Murao et al [ 106 ] reported a case of acute eosinophilic pneumonia triggered by COVID-19 that responded to treatment with prednisolone.…”

Section: Covid-19 In Patients With Eosinophil-associated Diseases Andmentioning

confidence: 99%

Eosinophils and COVID-19: diagnosis, prognosis, and vaccination strategies

Rosenberg

Foster

2021

Semin Immunopathol

View full text Add to dashboard Cite

The unprecedented impact of the coronavirus disease 2019 (COVID-19) pandemic has resulted in global challenges to our health-care systems and our economic security. As such, there has been significant research into all aspects of the disease, including diagnostic biomarkers, associated risk factors, and strategies that might be used for its treatment and prevention. Toward this end, eosinopenia has been identified as one of many factors that might facilitate the diagnosis and prognosis of severe COVID-19. However, this finding is neither definitive nor pathognomonic for COVID-19. While eosinophil-associated conditions have been misdiagnosed as COVID-19 and others are among its reported complications, patients with pre-existing eosinophil-associated disorders (e.g., asthma, eosinophilic gastrointestinal disorders) do not appear to be at increased risk for severe disease; interestingly, several recent studies suggest that a diagnosis of asthma may be associated with some degree of protection. Finally, although vaccine-associated aberrant inflammatory responses, including eosinophil accumulation in the respiratory tract, were observed in preclinical immunization studies targeting the related SARS-CoV and MERS-CoV pathogens, no similar complications have been reported clinically in response to the widespread dissemination of either of the two encapsulated mRNA-based vaccines for COVID-19.

show abstract

Eosinophilic pulmonary vasculitis as a manifestation of the hyperinflammatory phase of COVID-19

Abstract: Eosinophilic pulmonary vasculitis as a manifestation of the hyperinflammatory phase of

Cited by 10 publications

References 4 publications

Relapse of microscopic polyangiitis after vaccination against COVID‐19: A case report

Relapse of microscopic polyangiitis after vaccination against COVID‐19: A case report

Impact of Anti-Type 2 Inflammation Biologic Therapy on COVID-19 Clinical Course and Outcome

Eosinophils and COVID-19: diagnosis, prognosis, and vaccination strategies

Contact Info

Product

Resources

About